「trial」の検索結果

Manages Rule 30(b)(6) corporate representative deposition workflows — drafting notice topics with reasonable particularity, building examination outlines, defending designees, handling objections, and preserving binding admissions for summary judgment or trial. Use when drafting or responding to 30(b)(6) notices, selecting and preparing designees, building topic-by-topic outlines, or triaging scope and privilege disputes. Trigger keywords: 30(b)(6), corporate representative deposition, topic list, designee, notice analysis, deposition objections, corporate admissions.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze data from randomized controlled trials. Use when user mentions: treatment effects, ITT analysis, LATE, TOT, compliance analysis, attrition, balance checks, heterogeneous effects, RCT results, experimental analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Design randomized controlled trials for causal inference. Use when user mentions: randomized evaluation, RCT, field experiment, randomized experiment, treatment assignment, causal impact, experimental design, control group, intervention evaluation.

日本語の概要は準備中です。原文の説明を表示しています。

Estimates the minimum biological replicates (or cells/events) for a target power at a target FDR in genomics experiments using ssizeRNA, PROPER, powsimR for scRNA-seq, and pilot-data dispersion estimation from DESeq2/edgeR. Covers the biological-versus-technical replication distinction (technical replicates do not add degrees of freedom for biological inference), replicate-number-versus-sequencing-depth budgeting, scRNA-seq sample-versus-cell allocation under a pseudobulk model, and the critique that "n=3" is a publication convention rather than a power calculation. Use when budgeting a sequencing experiment, writing the sample-size justification in a grant, estimating replicates from pilot data, allocating a fixed budget between samples and depth, or planning scRNA-seq cohort size. For clinical-trial sample size see clinical-biostatistics/power-and-sample-size; for the power-given-n direction see experimental-design/power-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.

日本語の概要は準備中です。原文の説明を表示しています。

Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.

日本語の概要は準備中です。原文の説明を表示しています。

Build forest plots (HR, OR, RR, beta-coefficient summaries with CIs) and funnel plots (meta-analysis publication-bias diagnostics) using forestplot, metafor, ggforest, and MendelianRandomization with proper axis-scaling, summary-diamond placement, subgroup nesting, and Egger / trim-and-fill asymmetry tests. Use when summarizing effects across subgroups, trials, or instruments — meta-analysis, Mendelian randomization, subgroup HRs.

日本語の概要は準備中です。原文の説明を表示しています。

Build Sankey, alluvial, river, and CONSORT-style flow diagrams to visualize cohort transitions, cell-state changes, or pipeline filtering using ggalluvial, networkD3, plotly, and consort. Use when showing how entities move between categories across timepoints (cell states, drug response classes, patient flow through a trial) or filtering pipelines (variants filtered through QC stages).

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).

日本語の概要は準備中です。原文の説明を表示しています。

Performs subgroup and heterogeneous treatment effect (HTE) analyses for clinical trials. Covers Mantel-Haenszel pooling, Breslow-Day, interaction tests in regression, RERI for additive interaction, modern data-adaptive HTE methods (STEPP, SIDES, causal forests, X/R-learners), Bayesian shrinkage (Dixon-Simon, MAP, EXNEX), graphical multiplicity (Bretz-Maurer), and credibility frameworks (Sun BMJ, EMA 2019). Use when analyzing treatment effects across patient subgroups for regulatory submissions or precision-medicine claims.

日本語の概要は準備中です。原文の説明を表示しています。

Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level water treatment covering drinking water treatment, wastewater treatment, industrial water systems, membrane processes, and water reuse.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level nanomaterials engineering covering synthesis, characterization, properties at nanoscale, nanocomposites, safety, and industrial applications of nanomaterials.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level microbiology covering bacterial and viral biology, microbial physiology, pathogenesis, antimicrobial resistance, microbiome science, and industrial microbiology.

日本語の概要は準備中です。原文の説明を表示しています。

Quando o usuário quer criar ou otimizar paywalls in-app, telas de upgrade, modais de upsell ou feature gates. Use também quando o usuário mencionar "paywall", "tela de upgrade", "modal de upgrade", "upsell", "feature gate", "converter free para paid", "conversão freemium", "tela de expiração de trial", "tela de limite atingido", "prompt de upgrade de plano" ou "preço in-app". Distinto de páginas de preço públicas (veja page-cro) — esta skill foca em momentos de upgrade in-product onde o usuário já experimentou valor.

日本語の概要は準備中です。原文の説明を表示しています。

Retrieves scientific papers from PubMed and creates plain-language research summaries. Use when users ask about medical research, scientific studies, clinical trials, disease treatments, or want to understand recent scientific literature on any biomedical topic.

日本語の概要は準備中です。原文の説明を表示しています。

Europe PMC RESTful Web Service 多源文献聚合检索原子 skill。一次调用同时召回 PubMed + PMC + AGRICOLA + CABI + 预印本(bioRxiv / medRxiv / ChemRxiv 等)+ 灰色文献,自动按 PMID/PMCID/DOI 三级去重,返回完整元数据(含全文 OA 链接、citations metadata、grants 资助信息)。当任务出现 Europe PMC、多源文献聚合、广召回、RAG 检索、预印本搜索、bioRxiv、medRxiv、全文链接、DOI 检索、跨库去重、灰色文献、资助检索 等触发词时使用。**定位**:广召回 · 多源聚合 · RAG 友好(与 pubmed-eutils 互补——后者做精准官方源、Clinical Queries;本 skill 做"撒网"式广召回)。**不做**:NCBI E-utilities 直检(交给 pubmed-eutils)、临床试验(clinical-trials-v2)、全文 XML 抽取(bioc-fulltext-fetch)、实体识别(pubtator-entity-search)、证据分级(medical-evidence-grading)。

日本語の概要は準備中です。原文の説明を表示しています。

Europe PMC RESTful Web Service 多源文献聚合检索原子 skill。**使用本 skill 进行医学文献广召回 / RAG 知识库构建 / 跨库聚合 / 预印本扫描 / 全文链接发现**。一次调用同时召回 PubMed (MED) + PMC + AGRICOLA + CABI + 预印本(bioRxiv / medRxiv / ChemRxiv / Research Square)+ NCBI Bookshelf + 专利,自动按 PMID/PMCID/DOI 三级去重,返回完整元数据(全文 OA 链接、citations、grants 资助信息)。**定位:广召回 · 多源 · RAG 友好**(与 pubmed-eutils 互补 — 后者做单源精准官方检索 + Clinical Queries;本 skill 做"撒网"式多源聚合)。触发词:Europe PMC / EuropePMC / 多源文献聚合 / 广召回 / RAG 召回 / RAG 知识库 / 预印本搜索 / preprint search / bioRxiv / medRxiv / ChemRxiv / DOI 检索 / DOI lookup / 全文链接 / full-text links / OA 全文 / PMCID / 灰色文献 / grey literature / 跨库去重 / 资助检索 / grant search / NIH funded / Wellcome funded / citations metadata。**不做**:NCBI E-utilities 直检(→ pubmed-eutils)、临床试验注册(→ clinical-trials-v2)、全文 XML 抽取(→ bioc-fulltext-fetch)、实体识别(→ pubtator-entity-search)、证据分级(→ medical-evidence-grading)、参考文献终态写入(→ evidence-appendix-sync)。

日本語の概要は準備中です。原文の説明を表示しています。

対象skillを本物のclaudeセッション(tmux)でfresh contextのまま実走させて受け入れ確認したいとき、fork実行では観測できない自走・入れ子Skill・対話gateの本番挙動をgoal適合まで検証したいときに起動する。

Raw mechanical interfaces fusing Swiss typographic print with military terminal aesthetics. Rigid grids, extreme type scale contrast, utilitarian color, analog degradation effects. For data-heavy dashboards, portfolios, or editorial sites that need to feel like declassified blueprints.

日本語の概要は準備中です。原文の説明を表示しています。

This skill covers detecting sophisticated cyber-physical attacks that follow the Stuxnet attack pattern of modifying PLC logic while spoofing sensor readings to hide the manipulation from operators. It addresses PLC logic integrity monitoring, physics-based process anomaly detection, engineering workstation compromise indicators, USB-borne attack vectors, and multi-stage attack chain detection spanning IT-to-OT lateral movement through to process manipulation.

日本語の概要は準備中です。原文の説明を表示しています。

Knowledge base from the DoD M&Q BoK (the Manufacturing and Quality Engineering Body of Knowledge), v3.0 of July 2025, published by OUSD(R&E). Use for the manufacturing-and-quality view of the defense acquisition life cycle: what M&Q engineers do across the Adaptive Acquisition Framework phases (Pre-MDD, Materiel Solution Analysis, Technology Maturation and Risk Reduction, Engineering and Manufacturing Development, Production and Deployment, Operations and Support); the twelve M&Q threads (A–L) built on the '5 Ms'; manufacturing feasibility and producibility; Manufacturing Readiness Levels and assessments; Key/Critical Characteristics and process capability (Cp/Cpk, SPC); the standards stack (AS6500, AS9100/ISO 9001, AS9103, AS9145); technical reviews (ASR/PDR/CDR/PRR) and milestone gates; DCMA surveillance; industrial base and supply chain; and sustainment (LCSP, IPS, ILA, ISR). Scope is DoD acquisition M&Q practice on the Major Capability Acquisition path — it is a best-practice compilation, not policy, and is thin on detailed shop-floor process engineering, contract law, and the full text of the cited industry standards (which it names but does not reproduce).

日本語の概要は準備中です。原文の説明を表示しています。